Our study highlights the fact that RASGRP1 deficiency is a major risk factor for EBV‐driven lymphoproliferative disorders and demonstrates the critical function of RASGRP1 in pathways required for expansion of activated T cells in humans, a key step in immunity to EBV. Here, RASGRP1 is linked to lymphoproliferative syndrome.